Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study.

Bhat, Ramesh M; Leelavathy, B; Aradhya, Sacchidanand S; Gopal, Maragondanahalli G; Pratap, D V S; Mubashir, Mir; Srinivas, Putta; Pande, Sushil Y; Thavkar, Amit S

Bhat, Ramesh M; Leelavathy, B; Aradhya, Sacchidanand S; Gopal, Maragondanahalli G; Pratap, D V S; Mubashir, Mir; Srinivas, Putta; Pande, Sushil Y; Thavkar, Amit S.

Afiliación

Bhat RM; Department of Dermatology, Father Muller Medical College, Mangalore, India.
Leelavathy B; Diabetes and Shridi Skin Care Centre, Bengaluru, India.
Aradhya SS; Department of Dermatology, Victoria Hospital, Bengaluru, India.
Gopal MG; Department of Skin, Kempegowda Institute of Medical Sciences, Bengaluru, India.
Pratap DV; Durgabai Deshmukh Hospital and Research Centre, Hyderabad, India.
Mubashir M; Cuticare Centre, Hyderabad, India.
Srinivas P; Department of Dermatology, Osmania General Hospital, Hyderabad, India.
Pande SY; Department of Dermatology, Sparsh Hospital and Polyclinic, Nagpur, Maharashtra, India.
Thavkar AS; Department of Dermatology, Novartis India Limited, Mumbai, Maharashtra, India.

Indian Dermatol Online J ; 8(1): 16-24, 2017.

Article en En | MEDLINE | ID: mdl-28217466

Palabras clave

Interleukin (IL)-17A; PASI 75; plaque psoriasis; secukinumab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Indian Dermatol Online J Año: 2017 Tipo del documento: Article País de afiliación: India

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google